The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression

Although high serum levels of galactose-deficient-IgA1 (an important biomarker of IgA nephropathy (IgAN)), are found in most patients with IgAN, their relationship to disease severity and progression remains unclear. To help clarify this we prospectively enrolled 275 patients with IgAN and followed them for a median of 47 months (range 12–96 months). Serum galactose-deficient-IgA1 was measured at the time of diagnosis using a lectin-based ELISA and renal survival was modeled using the Cox proportional hazards method. The serum levels of galactose-deficient-IgA1 were higher in patients with IgAN compared to those in healthy controls. Importantly, in adjusted analysis, higher levels of galactose-deficient-IgA1 were independently associated with a greater risk of deterioration in renal function with a hazard ratio of 1.44 per standard deviation of the natural log-transformed galactose-deficient-IgA1 concentration. In reference to the first quartile, the risk of kidney failure increased such that the hazard ratio for the second quartile was 2.47, 3.86 for the third, and 4.76 for the fourth quartile of the galactose-deficient-IgA1 concentration. Hence, elevated serum levels of galactose-deficient-IgA1 are associated with a poor prognosis in IgAN.